SCHEMBL13721812

SCHEMBL13721812

Nn1nc(Sc2ccccc2)c2ccccc2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.40
▸ HTT P42858 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ RXFP1 Q9HBX9 2/20 0.40
▸ PRNP P04156 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ PPARG P37231 1/20 0.40
▸ NCOA2 Q15596 1/20 0.40
▸ ABCG2 Q9UNQ0 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ MAPT P10636 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ KAT2B Q92831 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13720706 0.89 DDAH1 (0.38) LMNAHTTNPSR1RXFP1PRNP
SCHEMBL13721065 0.88 SMN1; SMN2 (0.44) HTTNPSR1RXFP1PRNPCYP1A2
SCHEMBL13720537 0.88 NPC1 (0.41) LMNAHTTNPSR1CYP1A2CYP3A4
SCHEMBL13721157 0.76 ALDH1A1 (0.46) LMNAHTTCYP2C9ALDH1A1MAPT
SCHEMBL13721339 0.75 KAT2B (0.38) LMNANPSR1KDM4EKAT2BKMT2A
SCHEMBL1788116 0.70 ALDH1A1 (0.57) LMNAHTTNPSR1CYP1A2CYP3A4
SCHEMBL1786624 0.69 NPSR1 (0.56) LMNAHTTNPSR1ALDH1A1KDM4E
SCHEMBL1787409 0.69 SMN1; SMN2 (0.47) LMNAHTTNPSR1RXFP1ALDH1A1
SCHEMBL1788702 0.69 ALDH1A1 (0.40) LMNANPSR1ALDH1A1MAPTKDM4E
SCHEMBL1787363 0.67 TSHR (0.61) LMNACYP1A2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 — — US disclosed
WO-2012158399-A1 CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-22 — — WO disclosed
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNJ2 LMNA 1022/4885HTT 2126/4885NPSR1 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback